Clinical Trial Update: Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy [Phase 1]

View source ↗

Summary

Phase I pharmacokinetic trial of phenylbutyrate given as a continuous infusion in pediatric patients with refractory malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Neuroblastoma

Drugs mentioned

• Phenylbutyrate (phenylbutyrate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain Neoplasms, Neuroblastoma | Phase 1 | Status: COMPLETED